Literature DB >> 23806562

Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.

Qing Zhu1, Mei Liu, Liping Dai, Xia Ying, Hua Ye, Yusen Zhou, Suxia Han, Jian-Ying Zhang.   

Abstract

Since intracellular proteins involved in carcinogenesis have been shown to provoke autoantibody responses, autoantibodies can be used as probes in immunoproteomics to isolate, identify, and characterize potential tumor-associated antigens (TAAs). Once a TAA is identified, several approaches will be used to comprehensively characterize and validate the identified TAA/anti-TAA systems that are potential biomarkers in certain types of cancer. Our ultimate goal is to establish rigorous criteria for designation of an autoantibody to a TAA as a cancer biomarker, examine candidate TAAs for sensitivity and specificity of anti-TAA antibody response, and further develop customized TAA arrays that can be used to enhance anti-TAA antibody detection in cancer. This review will mainly focus on the recent advances in our studies using immunoproteomic approach to identify and characterize TAAs as biomarkers in cancer.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibody; Cancer; Immunodiagnosis; Immunoproteomics; Tumor-associated antigen

Mesh:

Substances:

Year:  2013        PMID: 23806562      PMCID: PMC3789855          DOI: 10.1016/j.autrev.2013.06.015

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  45 in total

1.  Why is Hu where? Shuttling of early-response-gene messenger RNA subsets.

Authors:  J D Keene
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

2.  Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.

Authors:  Koksun Looi; Roxanne Megliorino; Fu-Dong Shi; Xuan-Xian Peng; Yao Chen; Jian-Ying Zhang
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

Review 3.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

4.  Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.

Authors:  Jian-Ying Zhang; Roxanne Megliorino; Xuan-Xian Peng; Eng M Tan; Yao Chen; Edward K L Chan
Journal:  J Hepatol       Date:  2006-09-25       Impact factor: 25.083

5.  Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.

Authors:  Fu-Dong Shi; Jian-Ying Zhang; Daorong Liu; Ann Rearden; Max Elliot; Dan Nachtsheim; Tracy Daniels; Carlos A Casiano; Mary Jo Heeb; Edward K L Chan; Eng M Tan
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

6.  Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis.

Authors:  Tracy Daniels; Jianying Zhang; Israel Gutierrez; Max L Elliot; Brian Yamada; Mary Jo Heeb; Shaun M Sheets; Xiwei Wu; Carlos A Casiano
Journal:  Prostate       Date:  2005-01-01       Impact factor: 4.104

Review 7.  Autoantibodies to tumor-associated antigens: reporters from the immune system.

Authors:  Eng M Tan; Jianying Zhang
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  CIP2A inhibits PP2A in human malignancies.

Authors:  Melissa R Junttila; Pietri Puustinen; Minna Niemelä; Raija Ahola; Hugh Arnold; Trine Böttzauw; Risto Ala-aho; Christina Nielsen; Johanna Ivaska; Yoichi Taya; Shi-Long Lu; Shujun Lin; Edward K L Chan; Xiao-Jing Wang; Reidar Grènman; Juergen Kast; Tuula Kallunki; Rosalie Sears; Veli-Matti Kähäri; Jukka Westermarck
Journal:  Cell       Date:  2007-07-13       Impact factor: 41.582

9.  A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Authors:  E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma.

Authors:  J Y Zhang; E K Chan; X X Peng; E M Tan
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

View more
  21 in total

Review 1.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 2.  The Widening Sphere of Influence of HOXB7 in Solid Tumors.

Authors:  Maria Cristina Errico; Kideok Jin; Saraswati Sukumar; Alessandra Carè
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

3.  Unique topics and issues in rheumatology and clinical immunology.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

4.  Autoimmune response to PARP and BRCA1/BRCA2 in cancer.

Authors:  Qing Zhu; Su-Xia Han; Cong-Ya Zhou; Meng-Jiao Cai; Li-Ping Dai; Jian-Ying Zhang
Journal:  Oncotarget       Date:  2015-05-10

5.  Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers.

Authors:  Qian Yang; Michael H Roehrl; Julia Y Wang
Journal:  Oncotarget       Date:  2017-12-22

6.  Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Authors:  Anshu Rastogi; Amina Ali; Shyh-Han Tan; Sreedatta Banerjee; Yongmei Chen; Jennifer Cullen; Charles P Xavier; Ahmed A Mohamed; Lakshmi Ravindranath; Jigisha Srivastav; Denise Young; Isabell A Sesterhenn; Jacob Kagan; Sudhir Srivastava; David G McLeod; Inger L Rosner; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava; Alagarsamy Srinivasan
Journal:  Genes Cancer       Date:  2016-11

7.  Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma.

Authors:  Mohammad Zahid Mustafa; Viet Hung Nguyen; François Le Naour; Eleonora De Martin; Elvire Beleoken; Catherine Guettier; Catherine Johanet; Didier Samuel; Jean-Charles Duclos-Vallee; Eric Ballot
Journal:  J Transl Med       Date:  2016-01-16       Impact factor: 5.531

8.  Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.

Authors:  Rick L Evans; James V Pottala; Satoshi Nagata; Kristi A Egland
Journal:  BMC Cancer       Date:  2018-01-31       Impact factor: 4.430

9.  Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma.

Authors:  Xia Ying; Su-Xia Han; Chen-Chen He; Cong-Ya Zhou; Yi-Ping Dong; Meng-Jiao Cai; Xin Sui; Cheng-Xian Ma; Xiao Sun; Yuan-Yuan Zhang; Wen-Li Gou; Clifford Mason; Qing Zhu
Journal:  Oncotarget       Date:  2017-04-11

10.  Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients.

Authors:  Sheila María Álvarez-Fernández; Marco Barbariga; Luca Cannizzaro; Carlo Vittorio Cannistraci; Laura Hurley; Alan Zanardi; Antonio Conti; Francesca Sanvito; Anna Innocenzi; Nicolò Pecorelli; Marco Braga; Massimo Alessio
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.